Laverock Therapeutics to Present New Data on Programmable, Tunable, Stable and Specific Gene Silencing Platform at ESGCT STEVENAGE, United Kingdom, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced...

Laverock Therapeutics makes significant advances in its unique programmable gene silencing platform and announces pipeline focus on advanced therapies in oncology and genetic diseases Programmable, tunable, stable and specific gene silencing has been demonstrated across multiple target genes and multiple cell typesPoC achieved with concomitant silencing of more than one...

Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule STEVENAGE, United Kingdom, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced...

Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team STEVENAGE, United Kingdom, March 26, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced...